Ocugen's OCU410 Gene Therapy Wins FDA RMAT Designation for Geographic Atrophy

Ocugen announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OCU410 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).¹ RMAT designation is intended to expedite the development and review of regenerative medicine therapies addressing serious or life-threatening conditions with significant unmet need, and products receiving it are eligible for the combined benefits of the Fast Track and Breakthrough Therapy programs, including increased FDA interactions, eligibility for rolling BLA review, and potential accelerated approval and Priority Review.² The designation was supported by Phase 2 clinical data demonstrating clinically meaningful efficacy and a favorable safety profile.²

Shankar Musunuri, chairman, CEO, and co-founder of Ocugen, said the RMAT designation could accelerate OCU410's regulatory path while further differentiating its one-time treatment approach from current therapies that require chronic administration, noting that with an estimated 2 to 3 million people affected in the US and Europe, a number expected to grow as the population ages, geographic atrophy remains a leading cause of irreversible blindness in older adults and underscores the urgent need for new treatment options.²

How does OCU410 work, and what data support it?

OCU410 is a modifier gene therapy that uses an adeno-associated virus (AAV5) platform to deliver the RORA (RAR-related orphan receptor A) gene to retinal cells.³ The RORA protein plays a role in lipid metabolism, reduces lipofuscin deposits and oxidative stress, and has demonstrated anti-inflammatory activity along with complement system inhibition in preclinical studies, giving OCU410 a multifunctional mechanism intended to address several disease pathways at once rather than targeting a single pathway the way currently approved anti-complement therapies for GA do.³

Topline 12-month data from the Phase 2 ArMaDa trial showed that the dose selected for phase 3 development produced a statistically significant 31% reduction in lesion growth versus control (p<0.05), a treatment effect the company characterized as potentially twice as strong as the 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectively.⁴ No serious adverse events or adverse events of special interest related to OCU410 had been reported as of that data cutoff.⁴ OCU410 has also received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency.⁴

Why does a one-time gene therapy matter in this disease?

Current GA treatment options are limited to anti-complement therapies that require 6 to 12 intravitreal injections per year indefinitely, a chronic treatment burden that has been associated with substantial dropout rates in real-world practice.⁴ dAMD affects approximately 10 million Americans, with a global prevalence estimated at 266 million, and GA, its advanced form, is characterized by progressive, irreversible degeneration of the macula leading to permanent central vision loss.⁴ Because approved anti-complement therapies address only one of the several pathways involved in GA's multifactorial disease progression, Ocugen has positioned OCU410's multi-pathway mechanism as a differentiator from existing single-pathway options.³

What happens next?

Ocugen has stated its intention to initiate the OCU410 phase 3 registrational trial, with a broader company goal of three BLA filings within three years and potential BLA and MAA filings as early as 2028.⁴ With RMAT designation now secured, Ocugen will look to leverage the increased FDA engagement that designation provides as it finalizes its phase 3 trial design and moves toward that registrational filing timeline.

References

1. Ocugen, Inc. Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration. July 29, 2026.GlobeNewswire. https://www.globenewswire.com/news-release/2026/07/29/3335110/0/en/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-geographic-atrophy-secondary-.html
2. Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration. Published July 29, 2026. Accessed July 29, 2026. Investing News Network. https://investingnews.com/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-regenerative-medicine-advanced-therapy-designation-for-treatment-of-geographic-atrophy-secondary-to-dry-age-related-macula/
3. Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy. Published November 19, 2024. Accessed July 29, 2026. Ophthalmology Times. https://www.ophthalmologytimes.com/view/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for-geographic-atrophy
4. Ocugen, Inc. Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. March 24, 2026. https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-topline-12-month-data-phase-2-armada-clinical